10-QPeriod: Q1 FY2011

Merck & Co., Inc. Quarterly Report for Q1 Ended Mar 31, 2011

Filed May 9, 2011For Securities:MRK

Summary

Merck & Co., Inc. (MRK) reported strong financial results for the first quarter of 2011, with a significant increase in net income and earnings per share compared to the same period in the prior year. Total sales saw a modest increase, driven by robust growth in key pharmaceutical products like Januvia and Singulair, as well as positive contributions from the Animal Health and Consumer Care segments. The company's strategic focus on integrating the Schering-Plough merger appears to be yielding cost efficiencies, as evidenced by lower operating expenses and improved gross margins, even after accounting for restructuring charges. However, investors should note the ongoing impact of patent expirations on some established products, leading to sales declines in those areas. The company also incurred a significant arbitration settlement charge in the quarter. Merck continues to invest heavily in research and development, with a robust pipeline of new treatments under development across various therapeutic areas, including a promising hepatitis C treatment. The company also announced a pending acquisition of Inspire Pharmaceuticals. Overall, the results indicate a company navigating patent cliffs while investing for future growth and managing integration costs effectively.

Financial Highlights

49 data points
Beta

Revenue

$11.58B

64.9% Gross Margin

Net Income

$1.04B

9.0% Net Margin

EPS (Diluted)

$0.34

Total Assets

$105.86B

Cash & Equivalents

$11.70B

Free Cash Flow

$1.72B

Financial Statements
Beta
Revenue$11.58B
Cost of Revenue$4.06B
Gross Profit$7.52B
R&D Expenses$2.16B
SG&A Expenses$3.16B
Interest Expense$186.00M
Net Income$1.04B
EPS (Basic)$0.34
EPS (Diluted)$0.34
Shares Outstanding (Basic)3.08B
Shares Outstanding (Diluted)3.10B

Key Highlights

  • 1Net income attributable to Merck & Co., Inc. significantly increased to $1.043 billion ($0.34 EPS) in Q1 2011, up from $299 million ($0.10 EPS) in Q1 2010, indicating improved profitability.
  • 2Worldwide sales grew 1% to $11.6 billion, driven by strong performance in key products like Januvia, Janumet, Singulair, Remicade, and Isentress, alongside growth in Animal Health and Consumer Care segments.
  • 3The company reported improved gross margin of 64.9% in Q1 2011, up from 54.3% in Q1 2010, largely due to lower amortization of intangible assets and inventory step-up related to the merger, as well as manufacturing efficiencies.
  • 4Operating expenses were managed effectively, with Marketing and Administrative expenses declining 2% and research and development expenses increasing only 5% despite significant IPR&D impairment charges.
  • 5Merck incurred a $500 million arbitration settlement charge related to Remicade and Simponi distribution rights, which impacted 'Other (income) expense, net'.
  • 6The company announced an agreement to acquire Inspire Pharmaceuticals for approximately $430 million, signaling continued strategic investment in growth opportunities.
  • 7The company's robust R&D pipeline is highlighted by advancements in treatments for Hepatitis C (Victrelis) and a pediatric hexavalent combination vaccine.

Frequently Asked Questions

The significant increase in net income and EPS in the first quarter of 2011 compared to the first quarter of 2010 is primarily attributable to lower amortization of inventory step-up and lower restructuring costs. These factors, combined with improved gross margins due to manufacturing efficiencies and a favorable product mix, more than offset the negative impact of a $500 million arbitration settlement charge and increased in-process research and development (IPR&D) impairment charges.

Patent expirations for Cozaar and Hyzaar in April 2010 (US) and March 2010 (major European markets) have led to a substantial decline in sales for these products. The company reported a 46% decrease in sales for Cozaar/Hyzaar in the first quarter of 2011 compared to the prior year, and expects this trend to continue. This highlights the company's challenge in managing revenue while relying on newer products like Januvia to drive growth.

Merck is actively managing its cost structure through two main restructuring programs: the Merger Restructuring Program (integrating legacy Merck and Schering-Plough) and the 2008 Global Restructuring Program. In Q1 2011, the company recorded a net credit of $14 million in restructuring costs primarily due to a reduction in separation reserves, compared to $288 million in Q1 2010. While these programs have resulted in significant costs, they are contributing to improved operational efficiencies and lower expenses, with expected annual savings from the Merger Restructuring Program ranging from $2.7 billion to $3.1 billion by 2012.

The $500 million charge recorded in 'Other (income) expense, net' relates to the resolution of an arbitration proceeding with Johnson & Johnson concerning the distribution rights for Remicade and Simponi. Effective July 1, 2011, Merck will relinquish exclusive marketing rights in certain territories, while retaining rights in Europe, Russia, and Turkey. The profit split in retained territories will be 50/50, a change from the previous 58/42 split favoring Merck. This settlement impacts current quarter results but aims to clarify future revenue streams and partnership terms.